Английская Википедия:Idalopirdine
Материал из Онлайн справочника
Шаблон:Short description Шаблон:Drugbox
Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of October 2013 it is in phase III clinical trials.[2]
A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose.[3] Two further phase III trials failed too, the company confirmed in early 2017.[3]
See also
References
External links
- Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia Шаблон:Webarchive
- Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease Шаблон:Webarchive
Шаблон:Serotonergics Шаблон:Tryptamines